MedTrace Logo

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

NCT01579084 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.

Conditions

  • Rosacea
  • Erythema

Interventions

DRUG

AGN-199201 Formulation A

AGN-199201 Formulation A applied to the face as per protocol twice daily.

DRUG

AGN-199201 Formulation B

AGN-199201 Formulation B applied to the face as per protocol twice daily.

DRUG

AGN-199201 Formulation C

AGN-199201 Formulation C applied to the face as per protocol twice daily.

DRUG

AGN-199201 Vehicle

AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01579084 on ClinicalTrials.gov